Copyright
©2014 Baishideng Publishing Group Inc. All rights reserved.
World J Clin Oncol. Dec 10, 2014; 5(5): 1048-1054
Published online Dec 10, 2014. doi: 10.5306/wjco.v5.i5.1048
Published online Dec 10, 2014. doi: 10.5306/wjco.v5.i5.1048
Therapeutic strategy for postoperative recurrence in patients with non-small cell lung cancer
Tokujiro Yano, Seiichi Fukuyama, Department of Thoracic Surgery, National Hospital Organization Beppu Medical Center, Beppu 874-0011, Japan
Tatsuro Okamoto, Yoshihiko Maehara, Department of Surgery and Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka 812-8581, Japan
Author contributions: Each author contributed to this paper equally.
Correspondence to: Tokujiro Yano, MD, PhD, Department of Thoracic Surgery, National Hospital Organization Beppu Medical Center, 1473 Uchikamado, Beppu 874-0011, Japan. tokujiro@beppu.hosp.go.jp
Telephone: +81-977-671111 Fax: +81-977-675766
Received: December 25, 2013
Revised: January 23, 2014
Accepted: June 18, 2014
Published online: December 10, 2014
Processing time: 351 Days and 4.1 Hours
Revised: January 23, 2014
Accepted: June 18, 2014
Published online: December 10, 2014
Processing time: 351 Days and 4.1 Hours
Core Tip
Core tip: The postrecurrence survival in non-small cell lung cancer (NSCLC) is considered to largely depend on both the mode of first recurrence (distant, locoregional or combined) and the treatment modality. Therefore, the therapeutic strategy for treating postoperative recurrence in patients with NSCLC should be considered according to the mode of first recurrence. In this way, proper treatment specific to the mode of recurrence will be developed and improvements of the postrecurrence survival can be obtained.